Retroviral Integrase Inhibitor Pharmacokinetics
From Proteopedia
(Difference between revisions)
| Line 48: | Line 48: | ||
! N/A | ! N/A | ||
|} | |} | ||
| - | For Pharmacokinetic Data References, See: [[Retroviral Integrase Inhibitor Pharmacokinetics References|References]] | + | For Pharmacokinetic Data References, See: [[Treatments:Retroviral Integrase Inhibitor Pharmacokinetics References|References]] |
Current revision
| Retroviral Integrase Inhibitor Pharmacokinetics | |||
|---|---|---|---|
| Parameter | Raltegravir | Elvitegravir | MK-2048 |
| Tmax (hr) | 1.8 | 2-4 | N/A |
| Cmax (ng/ml) | 4253 | 2070 | N/A |
| Bioavailability (%) | 32 | ~30 | N/A |
| Protein Binding (%) | 83 | N/A | N/A |
| T1/2 (hr) | 10.8 | 7.6 | N/A |
| AUC (ng/ml/hr) | 10168 | 21200 | N/A |
| Dosage (mg) | 400 | 150 | N/A |
| Metabolism | Hepatic - (UGT1A1) | Hepatic - (CYP3A4) | N/A |
For Pharmacokinetic Data References, See: References
